logo

For the Inventor, By the Inventor

New York, NY, United States of America

Sloan-Kettering Institute for Cancer Research


USPTO Granted Patents = 517

% Expired Patents = 22.4



Forward Citations = 6,304

Loading Chart...
Loading Chart...

678 inventors (with patents filed for the assignee):

goldMedal Samuel J Danishefsky (76 out of 94 patents)

silverMedal Lloyd J Old (32 out of 122 patents)

bronzeMedal Ting-Chao Chou (28 out of 37 patents)

4.  Philip O Livingston (28 out of 34 patents)

5.  Alan N Houghton (26 out of 28 patents)

6.  Nai-Kong V Cheung (21 out of 56 patents)

7.  David A Scheinberg (21 out of 51 patents)

8.  Paul A Marks (21 out of 27 patents)

9.  Kyoichi A Watanabe (21 out of 24 patents)

10.  Richard A Rifkind (19 out of 22 patents)

11.  Kenneth O Lloyd (19 out of 28 patents)

12.  Herbert F Oettgen (19 out of 20 patents)

13.  Gabriela Chiosis (17 out of 36 patents)

14.  Kenneth Allen Savin (17 out of 22 patents)

15.  Ouathek Ouerfelli (16 out of 29 patents)


Core Competencies:
HSP90 Inhibitors
Multimodal Nanoparticles
Cancer Therapies
CDC7 Kinase Inhibitors
Antibodies
Neurodegenerative Diseases
Glycopeptide Constructs
Endothelial Cell Proliferation
Ocular Prosthesis
Circulating Exosomes
Thiohydantoins
Granaticin B

517 patents:

1. 12728282 - Systems and methods for high dose rate brachytherapy treatment planning using constraint optimization (2026-09-08),
2. 12697387 - CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND USE THEREOF (2026-08-04),
3. 12648963 - MIR200C-EPCAM AXIS REPROGRAMED IMMUNE CELLS FOR ENHANCED ANTI-TUMOR FUNCTION (2026-06-09),
4. 12616759 - USES OF LABELED HSP90 INHIBITORS (2026-05-05),
5. 12555672 - Detection of labels in biomedical images (2026-02-17),
6. 12478616 - PI3K inhibitors and uses thereof (2025-11-25),
7. 12473288 - Treatment of neurodegenerative diseases through inhibiton of Hsp90 (2025-11-18),
8. 12336902 - Ocular prosthesis with display device (2025-06-24),
9. 12331129 - Chimeric receptors targeting ADGRE2 and/or CLEC12A and uses thereof (2025-06-17),
10. 12227535 - Triterpene saponins, methods of synthesis and uses thereof (2025-02-18),
11. 12221489 - Antibodies to human B7x for treatment of metastatic cancer (2025-02-11),
12. 12161734 - Multimodal silica-based nanoparticles (2024-12-10),
13. 12121525 - Methods for treating GI syndrome and graft versus host disease (2024-10-22),
14. 12109189 - CDC7 kinase inhibitors and uses thereof (2024-10-08),
15. 11913021 - Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis (2024-02-27),
Sloan-Kettering Institute for Cancer Research is a world-renowned cancer research institute dedicated to advancing the understanding and treatment of cancer. With a focus on innovative research, exceptional patient care, and education, the institute has made significant contributions to the field of oncology. Their website provides valuable information about the institute's research programs, clinical trials, patient care services, and educational resources.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 8 2026

Sloan-Kettering Institute for Cancer Research
517 Patents

#38 in New York, NY

#65 in New York

#946 in US

#1,879 in the World

New York, NY (US)
New York, NY, United States of America

Sloan-Kettering Institute for Cancer Research

Forward Citations = 6,304

678 inventors:

goldMedal Samuel J Danishefsky (76 out of 94 patents)

silverMedal Lloyd J Old (32 out of 122 patents)

bronzeMedal Ting-Chao Chou (28 out of 37 patents)

4.  Philip O Livingston (28 out of 34 patents)

5.  Alan N Houghton (26 out of 28 patents)

Please report any incorrect information to [email protected]
Loading…